InMed Pharmaceuticals, Inc.

Ordinary Shares International Reporting
Verified Company Profile 1/26/2017
Contact Info
  • 350-409 Granville Street
  • Vancouver, BC V6C1T2
  • Canada

Business Description

Financial Reporting/Disclosure
Reporting Status International Reporting: TSX Venture Exchange
Audited Financials Audited
Latest Report Mar 31, 2017 Interim Financial Report
CIK 0001429816
Fiscal Year End 6/30
OTC Marketplace OTCQB
Profile Data
SIC - Industry Classification 2834 - Pharmaceutical preparations
Incorporated In: British Columbia, Canada
Year of Inc. Not Available
Employees Not Available
Company Officers/Contacts
Eric A. Adams CEO
Jeff Charpentier CFO
Chris Bogart Senior VP
Sazzad Hossain Chief Scientific Officer
Company Directors
Martin Bott Independent Director, Audit Committee Member
Adam Cutler Independent Director, Audit Committee Member
William Garner Independent Director, Compensation Committee Member
Andrew Hull Independent Director, Compensation Committee Member
Service Providers
Accounting/Auditing Firm Securities Counsel
Farris Vaughan Wills & Murphy LLP
25 Floor, 700 West Georgia Street
PO Box 10026
Pacific Centre South
Vancouver, BC, V7Y 1B3
Investor Relations Firm

Not Available
Company History
  • Formerly=Cannabis Technologies Inc. until 10-2014
  • Formerly=Meridex Software Corp. until 5-2014
  • Formerly=Meridex Network Corp. until 2-03
IMLFF Security Details
Share Structure
Market Value1 $31,622,472 a/o Jun 22, 2017
Authorized Shares Unlimited a/o Jan 19, 2017
Outstanding Shares 113,586,466 a/o Apr 08, 2017
-Restricted Not Available
-Unrestricted Not Available
Held at DTC Not Available
Float Not Available
Par Value No Par Value
Shareholders of Record 112 a/o Oct 25, 2016
Non US Stock Exchange Listing
IN - TSX Venture Exchange - Qualified
Short Selling Data
Short Interest 20,877 (151.29%)
May 15, 2017
Significant Failures to Deliver No

1Market Value calculated only for respective security